Hull M Louise, Gomez Raul, Nothnick Warren B, Gruemmer Ruth, Burns Katherine A, Johan Mohammed Zahied, Land Isabella R, Missmer Stacey A, Hummelshoj Lone, Greaves Erin, Bruner-Tran Kaylon L
The Robinson Research Institute, University of Adelaide, Adelaide, Australia.
Research Unit on Women's Health-INCLIVA, Institute of Health Research, Valencia, Spain.
Mol Hum Reprod. 2025 Jul 3;31(3). doi: 10.1093/molehr/gaaf022.
Endometriosis, defined as the growth of endometrial-like tissues outside the uterus, is a common disease among women. Numerous in vivo rodent models of endometriosis have been developed to explore multiple aspects of this poorly understood disease. Heterologous models utilize human endometrial tissues engrafted into immunocompromized mice, while homologous models engraft rodent endometrium into immunocompetent mice or rats. Heterologous models of endometriosis more closely replicate the human disease; however, the murine humoral immune response must be suppressed to prevent rejection of the xenograft tissue. Although the innate immune system remains intact, suppression of the humoral response leads to a markedly different local and systemic immune environments compared to humans. Despite this limitation, experiments using heterologous models have contributed significantly to our understanding of endometriosis establishment and progression, the pre-clinical effectiveness of various therapeutic strategies, and genetically modifiable host factors that contribute to disease. Unfortunately, a lack of harmonization of the models used by different laboratories has impeded the reproducibility and comparability of results between groups. Therefore, the World Endometriosis Research Foundation (WERF) formed an international working group of experts in heterologous models of endometriosis to develop guidelines and protocols that could contribute to unifying experimental approaches across laboratories. Nine critical variables were identified: (i) mouse strain; (ii) human tissue type; (iii) hormonal status of the human tissue donor; (iv) human tissue preparation; (v) method and location of tissue placement; (vi) hormonal status of the recipient animal; (vii) whether or not mice were engrafted with human immune cells; (viii) endpoint assessments; and (ix) number and type of replicates. Herein, we outline important considerations for each major variable and make recommendations for unification of approaches. Widespread adoption of harmonized protocols and implementation of standardized documentation and reporting should further improve the reproducibility and translation of experimental findings both within and between laboratories.
子宫内膜异位症被定义为子宫外出现类似子宫内膜的组织生长,是一种常见的妇科疾病。为了探究这种了解甚少的疾病的多个方面,人们已经建立了许多体内啮齿动物模型。异种模型利用移植到免疫缺陷小鼠体内的人子宫内膜组织,而同种模型则将啮齿动物子宫内膜移植到具有免疫活性的小鼠或大鼠体内。子宫内膜异位症的异种模型更接近人类疾病;然而,必须抑制小鼠的体液免疫反应以防止异种移植组织被排斥。尽管先天免疫系统保持完整,但与人类相比,体液反应的抑制导致局部和全身免疫环境明显不同。尽管存在这一局限性,但使用异种模型进行的实验对我们理解子宫内膜异位症的发生和发展、各种治疗策略的临床前有效性以及导致疾病的可遗传修饰宿主因素做出了重大贡献。不幸的是,不同实验室使用的模型缺乏一致性,阻碍了各研究组之间结果的可重复性和可比性。因此,世界子宫内膜异位症研究基金会(WERF)成立了一个国际专家工作组,专门研究子宫内膜异位症的异种模型,以制定有助于统一各实验室实验方法的指南和方案。确定了九个关键变量:(i)小鼠品系;(ii)人体组织类型;(iii)人体组织供体的激素状态;(iv)人体组织制备;(v)组织植入的方法和位置;(vi)受体动物的激素状态;(vii)小鼠是否植入了人类免疫细胞;(viii)终点评估;(ix)重复实验的数量和类型。在此,我们概述了每个主要变量的重要注意事项,并对统一方法提出了建议。广泛采用统一方案以及实施标准化文件记录和报告应进一步提高各实验室内部以及实验室之间实验结果的可重复性和转化性。